Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma
The Oncologist · 2025
DOI: 10.1093/oncolo/oyae354 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Daniel M Geynisman und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, United States. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Given the historical underrepresentation of racial minorities in clinical trials, little is known about racial differences in outcomes of first-line therapies for advanced renal cell carcinoma (aRCC). This study described patient characteristics and clinical outcomes of first-line therapies for aRCC, including nivolumab + ipilimumab, pembrolizumab + axitinib, and tyrosine kinase inhibitors, by race in the real-world setting.
Methods
We conducted a retrospective medical chart review of patients with intermediate/poor-risk clear-cell aRCC. Treating physicians abstracted patient data from electronic medical charts.
Results
Among 346 patients with intermediate/poor-risk aRCC, a higher proportion of African-American/Black (n = 78) versus White (n = 268) patients had poorer baseline functional performance (ECOG-PS ≥ 2: 37.2% versus 21.3%). African-American/Black patients trended toward numerically lower overall response rates and shorter overall survival for nivolumab + ipilimumab or pembrolizumab + axitinib than White patients.
Conclusions
These findings provide important insights into racial differences in first-line aRCC treatment outcomes within real-world settings. Additional research with larger sample sizes is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, United States.
- Real-World Evidence and Insights, Cardinal Health, Dublin, OH 43017, United States.
- Global Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, NJ 08648, United States.
Zitieren
APA
Geynisman, D. M., John, W. S., Miller, T. A., Asgarisabet, P., Guttenplan, S. B., Yin, X., Savill, K. M. Z., McAllister, L., & Rosenblatt, L. (2025). Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma. The Oncologist. https://doi.org/10.1093/oncolo/oyae354
Vancouver
Geynisman DM, John WS, Miller TA, Asgarisabet P, Guttenplan SB, Yin X, et al. Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma. The Oncologist. 2025. doi:10.1093/oncolo/oyae354
BibTeX
@article{Geynisman2025,
author = {Geynisman, Daniel M and John, William S and Miller, Taavy A and Asgarisabet, Parisa and Guttenplan, Sarah B and Yin, Xin and Savill, Kristin M Zimmerman and McAllister, Lindsay and Rosenblatt, Lisa},
title = {Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyae354}
}
EUVIMED